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Pancreatic cancer is the eighth major form of cancer-related death worldwide, causing 227000 deaths annually. Type-II diabetes is
widely considered to be associated with pancreatic cancer, but whether this represents a causal or consequential association is
unclear. We conducted a meta-analysis to examine this association. A computer-based literature search from 1966 to 2005 yielded
17 case–control and 19 cohort or nested case–control studies with information on 9220 individuals with pancreatic cancer. The age
and sex-adjusted odds ratio (OR) for pancreatic cancer associated with type-II diabetes was obtained from each study. The combined
summary odds ratio was 1.82 (95% confidence interval (95% CI) 1.66–1.89), with evidence of heterogeneity across the studies
(P¼0.002 for case–control and P¼0.05 for cohort studies) that was explained, in part, by higher risks being reported by smaller
studies and studies that reported before 2000. Individuals in whom diabetes had only recently been diagnosed (o4 years) had a 50%
greater risk of the malignancy compared with individuals who had diabetes for X5 years (OR 2.1 vs 1.5; P¼0.005). These results
support a modest causal association between type-II diabetes and pancreatic cancer.
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Although cancer of the pancreas accounts for only 3% of all
cancers worldwide (Parkin et al, 2002), its poor prognosis makes it
the eighth major form of cancer-related death worldwide, causing
more than 220000 deaths annually. Apart from cigarette smoking,
which has been estimated to cause about 30% of pancreatic cancers
(Doll and Peto, 1976; Baghurst et al, 1991), relatively little is known
about the other chief determinants of the disease, although other
lifestyle factors have been implicated, including obesity (Berrington
de Gonzalez et al, 2003) and type-II diabetes (Everhart and Wright,
1995).
As type-II diabetes frequently occurs with pancreatic cancer, it is
considered by many to be an important risk factor for the
malignancy. A meta-analysis of 20 studies conducted a decade ago
estimated that individuals with diabetes have a two-fold greater
relative risk (RR) of pancreatic cancer compared with individuals
without diabetes (Everhart and Wright, 1995). However, there is
also good evidence that pancreatic cancer is causally linked to the
onset of diabetes (Wang et al, 2003) and is possibly associated with
an abnormality of islet cell function.
A large number of new studies have since published on the
association between type-II diabetes and pancreatic cancer.
Therefore, the purpose of the current study was to update the
earlier meta-analysis to provide the most reliable information on
the size of the association, and to explore any underlying sources
of heterogeneity, including variations in the strength of the
relationship with duration of diabetes.
MATERIALS AND METHODS
Data sources
Relevant studies were identified through EMBASE, PUBMED and
MEDLINE using a combined text word and MESH heading search
strategy of pancreatic cancer (pancreas, tumour, malignancy) and
type-II diabetes (NIDDM, diabetes, adult-onset diabetes). Refer-
ences from identified studies, as well as from the previous review,
were also scanned to identify any other relevant studies.
Study selection and data synthesis
Studies were included in this systematic review if they had
published quantitative estimates and standard errors, or con-
fidence limits, of the association between type-II diabetes and
pancreatic cancer by January 2005. Studies were excluded if they
provided only an estimate of effect, with no means by which to
calculate the standard error, or if the estimates were not adjusted
by age. The variance of the log odds ratio (OR) from each study
was calculated by converting the 95% confidence interval (CI) to
its natural logarithm by taking the width of the CI and dividing by
3.92. If the variance was unavailable, P-values were used to
estimate the CI. Some studies provided more than one OR
according to the duration of diabetes before being diagnosed with
pancreatic cancer. To maintain consistency across studies, the ORs
for individuals diagnosed with diabetes 41 year prior to the
diagnosis of pancreatic cancer were extracted and combined.
Summary estimates were obtained separately for case–control and
cohort studies by means of a ‘random effects’ approach and studies
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defined as the inverse of the variance of the log OR (Woodward,
2005). In addition, studies that reported separate ORs for mutually
exclusive categories of duration since diabetes was diagnosed (e.g.
1–4 years, 5–9 years, 410 years) were pooled separately to
examine how the strength of the association varied with duration
of diabetes. Possible sources of heterogeneity were investigated by
comparing the results for studies combined with respect to
particular characteristics (e.g. sex, method of diagnosis of
diabetes). All analyses were performed using STATA, version 8.
RESULTS
A total of 17 case–control and 19 cohort or nested case–control
studies with information on a total of 9220 individuals with
pancreatic cancer had published estimates of the association
between diabetes and the malignancy. Six additional studies were
excluded from this review; one study had published the
standardised mortality ratio only (Kessler, 1970), and the
remaining five studies contained duplicate information (La
Vecchia et al, 1990; Davey Smith et al, 1992; Calle et al, 1998;
Silverman et al, 1999; La Coughlin et al, 2000). The summary
characteristics of included studies are shown in Tables 1 and 2. The
majority of the study populations were from either North America
(n¼16) or Europe (n¼14) with the remaining five studies from
either Australasia or South America. With the exception of one
study that had recorded diagnosis of diabetes by proxy, diagnosis
of diabetes was either through self-report, an oral glucose-
tolerance test, medical records or a combination of these three
methods.
The pooled OR for case–control studies was 1.94 (95% CI 1.53–
2.46) (Figure 1), this being nonsignificantly higher than the
summary estimate from cohort studies: 1.73 (1.59–1.88; Figure 2)
(P for heterogeneity¼0.37). The combined estimate from all
studies was 1.82 (95% CI 1.66–1.99). There was some evidence of
Table 1 Case–control studies of diabetes and pancreatic cancer
PC cases Controls Diabetes
First author and
year No. Source No. Source
Source
diagnosis
Duration
(years)
%P C
cases
Level of
adjustment
Relative
risk 95% CI
Cuzick, 1989 216 Newly diagnosed
patients, England
279 Hospital patients SR, MR 41 6.0 M Age, sex 2.59 0.63–16.1
2.0 F 6.64 1.33–65.2
Wynder, 1973 142 Patients, US 142 Hospital patients SR 42 5.0 M Age, sex, race,
hospital
1.00 0.31–3.12
16.7 F 7.80 1.90–38.5
Norell, 1986 99 Newly diagnosed
patients, Sweden
301 Community SR 45 4.0 Age, sex, residence 2.40 0.60–9.70
Frye, 2000 116 Patients, New
Zealand
232 Hospital patients MR 41 Age, sex 2.75 0.81–10.2
1.75 0.46–7.09
Farrow, 1990 148 Patients in cancer
registry US
188 Community P 43 7.1 Age, smoking,
education
6.70 1.80–24.9
Jain, 1991 249 Newly diagnosed
patients, Canada
505 Community SR, P 5–10 3.8 Age, sex, smoking,
energy and fiber
intake
2.14 0.75–6.17
Lin, 1981 109 Hospitalised
patients, US
109 Hospital patients SR 41 7.4 Age, sex, race,
marital status,
hospital
0.78 0.28–2.09
Bueno de Mesquita,
1992
176 Patients,
Netherlands
487 Community SR, P 41 6.4 M Age, proxy,
smoking
0.73 0.27–2.00
7.3 F 0.93 0.35–2.50
Ekoe, 1992 179 Patients, Quebec 239 Community SR 41 NA Age, sex, smoking,
education
2.52 1.04–6.11
Kalapothaki, 1993 181 Hospitalised
patients, Greece
362 Hospitalised
patients
SR 410 5.0 Age, sex, hospital 3.60 1.80–7.10
Silverman, 2001 526 Hospitalised
patients, US
2153 Community SR, P 2–4 NA Age, sex, race, area,
smoking, alcohol,
BMI
1.40 0.70–2.40
Gold, 1985 201 Newly diagnosed
patients, US
402 Hospitalised
patients
SR, P 42 10.0 Age, sex, race,
hospital
0.63 0.34–1.15
La Vecchia, 1994 362 Hospitalised
patients, Italy
1089 Hospitalised
patients
SR 41 14.4M Age, sex, education,
BMI
2.60 1.80–4.80
9.8 F 1.40 0.80–2.50
Bonelli, 2003 202 Hospitalised
patients, Italy
406 Hospitalised
patients
SR 41 18.3 Age, sex, centre,
education,
occupation,
tobacco, alcohol
2.80 1.63–4.76
Lee, 1996 282 Hospitalised
patients, Taipei
282 Hospital SR 41 28.7 Age, sex, smoking,
alcohol
2.84 1.80–4.52
Gullo, 1994 720 Hospitalised
patients, Italy
720 Hospitalised
patients
SR, MR 41 13.6 Age, social class,
region, hospital
1.80 1.30–2.50
O’Mara, 1985 93 Hospitalised
patients, US
NA Hospitalised
patients
SR NA 7.6 Age 2.40 1.80–3.50
PC¼pancreatic cancer; SR¼self-reported diabetes; MR¼medical record of diabetes; P¼proxy provided information on diabetes status; NA¼data not available.
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cohort studies (P¼0.05) that was that was not explained by
differences in strength of effect between men and women,
adjustment for cigarette smoking or the method of diagnosis of
diabetes (Figure 3). Furthermore, there was no difference in the
summary RR from those studies that had adjusted for variables
other than age and sex compared to those studies that were unable
to adjust for other potential confounders (RR 1.85 vs 1.80;
Table 2 Cohort and nested case–control studies of diabetes and pancreatic cancer
Diabetes
PC among individuals
with diabetes
First author and
year Cohort source
Source of
diagnosis Duration
No. PY
follow-up Source
No. of
cases
Level of
adjustment
Relative
risk 95% CI
Ragozzino, 1982 Rochester, US MR 41 9800 MR, DC 3 M Age, sex 2.70 0.60–9.50
2 F 2.50 0.30–18.4
Whittemore, 1983 50000 students,
Harvard University, US
SR 46 NA DC 3 Age 6.08 0.99–47.0
Rulyak, 2003 251 subjects,
Washington, US
SR NA NA MR, P, DC NA Age, smoking,
sex, prior
history of non-
PC
2.10 0.40–10.9
Hiatt, 1988 122894, San Francisco,
US
SR 45 NA MR, CR 5 Age, sex, race,
smoking,
alcohol, coffee
4.50 1.20–16.7
Balkau, 1993 6988 male civil
servants, France
OGTT 42 NA MR, P NA Age, smoking 3.60 1.00–13.0
Shibata, 1994 13976 Southern
California retirees, US
SR ¼o4 3057 MR 4 Age, sex,
smoking
3.63 1.22–10.8
Inoue, 2003 200, Japan SR 41 NA MR, CR NA Age, sex, family
history, alcohol,
exercise, diet
2.07 1.14–3.74
1.29 0.46–3.56
Batty, 2004 18006 male civil
servants, UK
OGTT NA NA DC 4 Age,
employment,
smoking, SBP,
physical activity,
disease history
3.99 1.44–11.0
Jee, 2005 1298385, Korea OGTT 41 NA MR, CR NA Age, smoking,
alcohol use
1.71 1.42–2.06
1.71 1.25–2.34
Lund Nilsen 2000 31000 M SR NA 6181 CR 4M Age, sex 1.10 0.40–3.00
32374 F, Norway 8059 3 F 0.80 0.30–2.70
Mills, 1988 34000 Adventists,
California
SR 41 9683 DC 8 Age, sex 3.43 1.47–7.94
Gapstur, 2000 20473 M, 15183 F,
Chicago
SR NA NA DC NA Age 2.48 1.20–4.49
Stolzenberg-
Solomon, 2002
29084 M, Finland SR 45 10669 CR, MR 14 Age, smoking,
occupational
activity, asthma,
blood pressure
2.23 1.08–4.60
Lin, 2002 110792, Japan SR 41 20859 M,
15389 F
DC 17 Age, sex, and
smoking
2.10 1.20–3.60
9 1.50 0.73–3.12
Friedman, 1993 175000, San Francisco SR 41 NA MR, CR Age, weight 2.37 1.46–3.85
Adami, 1994 1.2 million, Sweden Hospitalised
patients
41 143618 M CR 68 M Age, sex 1.40 1.10–1.80
119643 F 88 F 1.50 1.20–1.80
Coughlin, 2004 467922 M, 588322 F,
Columbia and Puerto
Rico
SR 41 NA DC NA Age, sex, race,
education,
family history,
BMI, smoking,
alcohol, diet
history
1.48 1.27–1.73
1.44 1.21–1.72
Chow, 1995 134096 hospitalised for
diabetes, Sweden
Hospitalised
patients
41 432643 M CR 303 Age, sex, year
of follow-up
1.88 1.62–2.10
468493 F 347 1.97 1.77–2.19
Wideroff, 1997 109581 hospitalised for
diabetes, Denmark
Hospitalised
patients
41 628129 MR, CR 417 Age, sex, year
of follow-up
1.70 1.50–2.50
1.60 1.40–2.90
PC¼pancreatic cancer; MR¼medical record of diabetes; SR¼self-reported diabetes; OGTT¼oral glucose tolerance test; P¼proxy provided information on diabetes status;
NA¼data not available; DC¼death certificate; CR¼case-record form; M¼male; F¼female.
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tended to report higher RRs compared with larger studies
(P¼0.02). In addition, the summary estimate from studies that
were published before 2000 was significantly higher than those
studies published after this date: 1.90 (95% CI 1.67–2.15) vs 1.62
(95% CI 1.48–1.78): P¼0.046.
Nine studies had reported mutually exclusive categories for the
duration of diabetes that were broadly similar across the studies:
o4 years, 5–9 years and 410 years. Individuals who had the
shortest history of diabetes (o4 years) had more than a 50%
greater risk of developing pancreatic cancer than individuals who
had diabetes for between 5 and 10 years or for more than 10 years
(OR 2.1 95% CI 1.9–2.3 vs OR 1.5 95% CI 1.3–1.8; Figure 4).
DISCUSSION
The findings from this review suggest that earlier reports of a more
than two-fold excess risk of pancreatic cancer among individuals
with type-II diabetes are likely to have overestimated the strength
of the association (Ragozzino et al, 1982; Friedman and Van Den
Eeden, 1993; Everhart and Wright, 1995). Although the current
data suggest an 80% greater risk of pancreatic cancer among
individuals with type-II diabetes, even this may be an exaggeration
of the true strength of the relationship, as it does not consider the
considerable potential for reverse causality.
The RR of pancreatic cancer was demonstrated to be negatively
associated with the duration of diabetes. Among individuals with a
long history of diabetes (45 years), the excess RR of pancreatic
cancer was about 50% lower than in individuals for whom the
duration of diabetes was shorter (RR 1.5 vs 2.1; P¼0.005). This
supports the hypothesis that, in some cases, diabetes may be an
early manifestation of the tumour, as otherwise the RR would be
expected to increase, rather than decrease, with duration of
diabetes. In an earlier review similar RRs of pancreatic cancer by
duration of diabetes were reported (Everhart and Wright, 1995)
but, the categories for duration of diabetes, unlike in the current
meta-analysis, were not mutually exclusive (i.e.45 years diabetes
duration was a subset of the 41 year group) and therefore, the RR
for the 41 year duration of diabetes was likely to have been
diluted by the inclusion of cases with a longer history of diabetes
(and hence a smaller RR).
Evidence from the literature further supports the hypothesis that
pancreatic cancer can induce a diabetic state. First, several studies
have shown that the risk of pancreatic cancer among individuals
with diabetes is lessened after exclusion of those with less that 1
year of diabetes, indicating that a component of the RR associated
with diabetes is explained by individuals who are diagnosed with
the malignancy within a short period of being diagnosed with
diabetes (Ragozzino et al, 1982; Cuzick and Babiker, 1989).
Second, in studies among individuals with pancreatic cancer who
underwent tumour resection, insulin sensitivity and diabetes status
Relative risk
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Figure 1 Relationship between type-II diabetes and risk of pancreatic cancer in case–control studies. Black square¼point estimate (with area
proportional to statistical ‘information’, based on inverse of variance of the OR provided by each study) and horizontal line¼95% CI for observed effect in
each study. *¼adjustment for age and sex; **¼adjustment for age, sex, smoking or a marker of social class; ***¼adjustment for age, sex, smoking and
social class; ****¼adjustment for age, sex, smoking, social class and dietary variables.
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surgery (Permert et al, 1993). And third, molecular studies of sera
from pancreatic cancer patients have identified peptides that are
suggested to be diabetogenic (Wang et al, 2003).
Although the above arguments support the idea of reverse
causality, the finding of a 50% increased RR of pancreatic cancer
among individuals with chronic diabetes (45 years) supports a
modest causal relationship between diabetes and pancreatic
cancer. This is true especially when considering that in individuals
with a long history of diabetes (45 years), it is unlikely that a
malignancy that has a particularly low 1-year survival rate (fewer
than 20% of individuals are alive at 1-year following diagnosis)
could induce diabetes many years prior to its diagnosis. In
addition, the presence of a graded dose–response association
between fasting glucose and pancreatic cancer, reported by some
large prospective studies, supports a causal relationship (Batty
et al, 2004; Jee et al, 2005).
Inherent in any review process of published studies is the
possibility of publication bias that may have resulted in an
overestimate of the size of any association between two variables.
There was some evidence to suggest that there was some
publication bias such that the smaller studies were more likely to
report a positive association between diabetes and pancreatic
cancer. However, the exclusion of any small negative studies is
unlikely to have materially altered the overall summary estimate.
Confounding is also likely to have been present since diabetes and
pancreatic cancer share several risk factors such as cigarette
smoking and obesity. However, adjustment for a wide range of
potential confounders only marginally attenuated the relationship
between diabetes and pancreatic cancer. It is also possible that the
use of aspirin and other nonsteroidal anti-inflammatory drugs
(NSAIDS) may have been a potential confounder. For example, in a
prospective follow-up study of over 28000 postmenopausal
women, women who reported using aspirin and other NSAIDS
had a significantly lower RR of pancreatic cancer compared to
non-users (RR 0.57 95% CI 0.36–0.90) (Anderson et al, 2002). In
recent years, individuals with diabetes have been more likely to
receive advice to take aspirin than people without diabetes in order
to lower the risk of cardiovascular disease (CVD). For example, in
the UK Prospective Diabetes Study, it was reported that between
1996/1997 and 2000/2001, aspirin use in patients without pre-
existing CVD increased from 17 to 31% (Po 0.0001) (Cull et al,
2004). Aspirin has been reported to reduce the risk of several types
of cancer (Garcia Rodriguez and Huerta-Alvarez, 1998; Thun et al,
1993); hence, the association between diabetes and pancreatic
cancer may have been attenuated by aspirin use and indeed in
studies published before 1995, the RR was significantly higher than
in those published after this date (RR 2.3 vs 1.8).
Furthermore, most studies included in this review did not
differentiate between Type-I and Type-II diabetes, which may have
slightly underestimated the overall association, since it has been
reported that Type-1 diabetes is not associated with pancreatic
cancer (Zendehdel et al, 2003). The literature, however, regarding
cancer mortality among individuals with type 1 diabetes, is limited
by small sample size and short length of follow-up (Mihara et al,
1986; Martinenghi et al, 1997) and therefore do not preclude a
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Figure 2 Relationship between type-II diabetes and risk of pancreatic cancer in cohort studies (conventions as in Figure 1).
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majority of individuals with diabetes included in these studies had
type-II diabetes, since this is by far the most common form
particularly in older individuals. Additional limitations of this
review include the reliance, in the large majority of studies, on self-
reported diabetes and the potential for misclassification on death
certificates of site-specific cancers, although the sensitivity
analyses did not show any difference in the risk between those
studies that used self-reported diabetes compared with those that
diagnosed diabetes either through medical records or by an oral
glucose tolerance test.
To date, only cigarette smoking, and possibly obesity, has been
identified as being causally associated with pancreatic cancer. The
evidence from this review indicates that type-II diabetes is likely to
be a third modifiable risk factor (Knowler et al, 2002; Davey Smith
et al, 2005) and unless the increasing worldwide prevalence of all
three risk factors is halted, the incidence of pancreatic cancer will
rise substantially within the next couple of decades.
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